Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which prevents the normal production of blood cells. The condition is a primary subtype of myeloproliferative neoplasms (MPNs) and, in some cases, starts as another MPN. Risk factors for primary MF are unclear, although a history of polycythemia vera (PV) or essential thrombocythemia (ET) are risk factors for development of secondary MF. The disease is stratified as low, intermediate, or high risk using various International Prognostic Scoring System scales, and the prognosis depends on individual risk factors including age, comorbidities, and treatment response.

Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
View More
Patrick DalyMyelofibrosis | February 29, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyeloproliferative Neoplasms | December 13, 2023
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Sangeetha Venugopal, MDMyelofibrosis | December 13, 2023
Venugopal highlights myelofibrosis research at ASH 2023.
Haifa Kathrin Al-Ali, MDMyelofibrosis | December 13, 2023
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Melissa BadamoMyelofibrosis | December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Nico Gagelmann, MDMyelofibrosis | December 12, 2023
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
Emily HayesMyelofibrosis | December 13, 2023
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Emily HayesMyelofibrosis | December 13, 2023
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Emily HayesMyelofibrosis | December 13, 2023
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Blood Cancers Today Staff WritersMyelofibrosis | December 8, 2023
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 7, 2023
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
Patrick DalyMyelofibrosis | December 13, 2023
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Blood Cancers Today Staff WritersMyelofibrosis | February 2, 2024
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
The use of combination therapies including XPO1 inhibitor selinexor is a potentially effective therapeutic strategy in MF.
Patrick DalyMyeloproliferative Neoplasms | December 6, 2023
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 13, 2023
Review more from the post-hoc time-dependent analysis of the phase III Simplify-1, Simplify-2, and MOMENTUM trials.
Melissa BadamoMyelofibrosis | November 30, 2023
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Melissa BadamoMyelofibrosis | December 1, 2023
The multicenter trial studied genetic mutations across three cohorts.
Melissa BadamoMyelofibrosis | November 17, 2023
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Patrick DalyMyelofibrosis | November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Melissa BadamoMyelofibrosis | November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Melissa BadamoMyelofibrosis | October 13, 2023
82.5% of MF patients experienced rapid significant decreases in palpable spleen size after two months of ruxolitinib therapy.
Melissa BadamoMyelofibrosis | February 8, 2024
The median duration of therapy is around three years in patients with intermediate or high-risk MF.
Patrick DalyMyelofibrosis | October 12, 2023
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Sangeetha Venugopal, MDMyelofibrosis | February 8, 2024
Myelofibrosis Awareness Day is marked on September 20th each year.
Leah LawrenceMyelofibrosis | February 8, 2024
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | February 8, 2024
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | October 11, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cecilia BrownMyelofibrosis | August 23, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Cecilia BrownMyelofibrosis | August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Cecilia BrownMyelofibrosis | October 11, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodIndolent B-Cell Lymphoma | October 15, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Cecilia BrownMyelofibrosis | July 21, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Cecilia BrownMyeloproliferative Neoplasms | July 10, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownMyelofibrosis | February 8, 2024
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Cecilia BrownMeeting News | September 20, 2023
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Keightley AmenMyelofibrosis | February 8, 2024
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
Keightley AmenMyelofibrosis | September 5, 2023
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
Cecilia BrownMyeloproliferative Neoplasms | June 8, 2023
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Latest News

February 29, 2024